AstraZeneca nabs priority review for Lynparza in prostate as PARP inhibitors expand to more cancers
Lynparza keeps rolling.
Three weeks after the FDA cleared the AstraZeneca drug as a first-line treatment of a particular form of advanced pancreatic cancer, the agency has granted priority review for the drug as a second-line treatment of a particular form of advanced prostate cancer. A PDUFA date is set for the second quarter of 2020.
The news is another notch in the belt for an R&D program and an oncology pipeline that was struggling just three years ago. Lynparza, a PARP inhibitor, and Imfinzi, AstraZeneca’s CTLA4 immunotherapy, will each finish 2019 with over $1 billion sales, and they only continue to expand their potential market. Last week, a Lynparza combo got priority review for a form of advanced ovarian cancer and yesterday an Imfinzi combo earned orphan designation for liver cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.